Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olesoxime in SMA Type 2/3
NCT01302600Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2010
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in spinal muscular atrophy (SMA) comparing Olesoxime with Placebo (2 arms). Primary endpoint: Motor Function Measure at 24 months. Started Nov 2010; status: completed.
02
Drugs
olesoxime
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT01302600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01302600.